Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

(Reuters) - Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

“These data support our efforts to bring a new shingles vaccine to global markets,” stated George Simeon, Curevo’s Chief Executive Officer. “Though somewhat unsurprising, given amezosvatein also ...

General Medicines Growth: 7% for the quarter. Vaccines Sales Decline: 15% for the quarter due to lower sales of Arexvy and Shingrix. Core Operating Profit Growth: 5% excluding COVID. Core EPS ...